ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs. The guidance identifies seven key interventions which, in synergistic combination, have been shown by evidence and experience to be effective in the prevention and control of infectious diseases that affect people who inject drugs.
The full report is available in English. A summary is available in all EU languages, Icelandic and Norwegian
At a glance: read the Guidance in brief
Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA
5 Dec 2018 - The main objective of this guidance is to provide scientific advice, based on an evidence-based assessment of targeted public health interventions, to facilitate effective screening and vaccination for priority infectious diseases among newly arrived migrant populations to the EU/EEA. It is intended to support EU/EEA Member States to develop national strategies to strengthen infectious disease prevention and control among migrants and meet the health needs of these populations.
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
5 Dec 2018 - The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance